Zura Bio Limited (NASDAQ:ZURA) Receives $14.33 Consensus Target Price from Analysts

Zura Bio Limited (NASDAQ:ZURA) has earned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $14.33.

Several research firms have recently weighed in on ZURA. Chardan Capital reduced their price objective on Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, March 26th. Guggenheim reissued a “buy” rating and set a $15.00 price target on shares of Zura Bio in a research report on Wednesday, March 26th. Oppenheimer reduced their price target on Zura Bio from $19.00 to $17.00 and set an “outperform” rating on the stock in a research report on Friday, May 9th. Finally, HC Wainwright reissued a “buy” rating on shares of Zura Bio in a research report on Thursday, April 3rd.

Hedge Funds Weigh In On Zura Bio

Institutional investors have recently made changes to their positions in the business. American Century Companies Inc. acquired a new position in shares of Zura Bio in the 4th quarter valued at approximately $27,000. Prudential Financial Inc. acquired a new position in shares of Zura Bio in the 4th quarter valued at approximately $28,000. Two Sigma Advisers LP acquired a new position in shares of Zura Bio in the 4th quarter valued at approximately $32,000. ProShare Advisors LLC acquired a new position in shares of Zura Bio in the 4th quarter valued at approximately $35,000. Finally, XTX Topco Ltd acquired a new position in shares of Zura Bio in the 4th quarter valued at approximately $44,000. 61.14% of the stock is owned by institutional investors and hedge funds.

Zura Bio Price Performance

NASDAQ ZURA opened at $1.00 on Friday. The firm has a market capitalization of $68.20 million, a P/E ratio of -1.42 and a beta of 0.05. Zura Bio has a 1-year low of $0.97 and a 1-year high of $5.56. The business’s 50-day simple moving average is $1.23 and its 200-day simple moving average is $1.81.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). On average, equities research analysts expect that Zura Bio will post -0.65 EPS for the current fiscal year.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.